BioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?

In October 2026, BioNTech reported that its AHEAD-MERIT Phase 2/3 trial of mRNA cancer candidate BNT113 plus pembrolizumab in advanced HPV-linked head and neck cancer did not meet its first primary endpoint of improving progression-free survival versus pembrolizumab alone, although the study continues to assess overall survival. This outcome highlights both the scientific difficulty of translating mRNA technology into effective solid-tumor therapies and the clinical importance now placed on...